Company Biovica International AB (publ) Nasdaq Stockholm
Equities
SE0008613731
Biotechnology & Medical Research
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Blood-based Biomarker Assays
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +65.43% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
96.3
%
| 2 | 95.0 % | 3 | 96.3 % | +67.68% |
European Union excluding Sweden
3.7
%
| 0 | 5.0 % | 0 | 3.7 % | +22.55% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 09-12-31 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 22-12-31 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 21-12-31 |
Tomas Andersson
COO | Chief Operating Officer | 64 | 19-12-31 |
Joakim Arwidson
LAW | General Counsel | 56 | 20-12-31 |
Helle Fisker
SAM | Sales & Marketing | 55 | 20-12-31 |
Corporate Officer/Principal | 58 | 19-11-17 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 64 | 19-03-19 | |
Annika Berg
BRD | Director/Board Member | 61 | 19-12-31 |
Maria Holmlund
BRD | Director/Board Member | 68 | 15-12-31 |
Director/Board Member | 73 | 13-12-31 | |
Anders Rylander
CEO | Chief Executive Officer | 54 | 09-12-31 |
Director/Board Member | 58 | 12-12-31 | |
Henrik Osvald
BRD | Director/Board Member | 65 | 18-12-31 |
Director/Board Member | 59 | 19-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 6,271,293 | 0 | 0 | 92.54 % |
Stock B | 1 | 77,784,267 | 77,784,267 ( 100.00 %) | 0 |
Company contact information
Biovica International AB
Dag Hammarskjölds väg 54B Uppsala Science Park
752 37, Uppsala
+46 1 84 44 48 30
http://www.biovica.comSector
Sales per region
1st Jan change | Capi. | |
---|---|---|
-16.10% | 11.41B | |
+67.65% | 3.81B | |
-14.31% | 2.16B | |
-26.03% | 1.56B | |
+36.95% | 1.19B | |
-2.40% | 760M | |
-19.00% | 506M | |
-38.57% | 444M | |
+13.72% | 339M |